MINK THERAPEUTICS INC (INKT)
US6036931029 - Common Stock
On Tuesday, there are stocks with unusual volume. Let's take a look.
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
MiNK Reports First Quarter 2024 Results
MiNK Reports First Quarter 2024 Results
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American...
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Top movers in Monday's pre-market session
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor...
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid modelsMiNK-215 exhibits potent anti-tumor activity through multiple mechanisms...
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023
INKT stock results show that MiNK Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips MiNK Therapeutics (NASDAQ:INKT) just reported results for the fourth quarter of...
MiNK Reports Fourth Quarter and Year-End 2023 Results
MiNK Reports Fourth Quarter and Year-End 2023 Results
Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced...
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
Treatment with agenT-797 Showed Improved Survival in Severe Respiratory Distress
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell...
MiNK Therapeutics Reports Third Quarter 2023 Results
MiNK Therapeutics Reports Third Quarter 2023 Results
MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months...
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1First-of-a-kind persistence for an allogeneic cell...
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...